

P20854.A10



IFW
1644/18

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Hiroshi SHIKU et al.

Group Art Unit : 1644

Appln. No : 09/787,916

Examiner : Ewoldt

I.A. Filed : September 30, 1999

For : METHOD FOR INDUCING CELLULAR IMMUNITY AND CELLS
HAVING INDUCED CELLULAR IMMUNITY

SECOND SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

U.S. Patent and Trademark Office
220 20th Street S.
Customer Window, Mail Stop _____
Crystal Plaza Two, Lobby, Room 1B03
Arlington, VA 22202

Sir:

Further to the Information Disclosure Statements filed July 9, 2001 and August 8, 2002 and in accordance with the duty of disclosure under 37 C.F.R. 1.56, 1.97, and 1.98, Applicants hereby brings the following information to the attention of the Examiner in charge of the above-identified application, which includes information cited and discussed in a Chinese Office Action issued in connection with counterpart Chinese Application No. 99811692.0, mailed April 30, 2004. A copy of the Chinese Office Action, accompanied by an English language translation is being submitted herewith. The Examiner is invited to review the Chinese Office Action to inspect the relevance indicated therein with respect to the cited information.

Xiaogang GU et al., "Induction of CD8+ Cytotoxic T Lymphocytes with MHC Class I Restriction by a Soluble Truncated Oncoprotein", Acta Med. Nagasaki, Vol. 42, pp. 19-24 (1997), accompanied by a separate abstract.

P20854.A10

A copy of the above-noted document is enclosed together with a duly completed Form PTO-1449. The Examiner is accordingly requested to consider this document, and to make it of record in this application by initialing in the appropriate space on the Form-1449. Applicants respectfully request that the Examiner include a copy of the initialed Form PTO-1449 with the next communication from the U.S. Patent and Trademark Office.


In accordance with 37 C.F.R. 1.97(e), the undersigned hereby states that each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement.

Applicants note that this disclosure statement is being filed after close of prosecution and with certification. Therefore, a check including the amount of \$180.00 is enclosed. However, if the fee is deficient and/or if any additional fee is required for consideration of this disclosure statement, including any fee under 37 C.F.R. 1.17(p), Applicants hereby authorize that any required fee be charged to Deposit Account No. 19-0089.

Any comments or questions concerning this application can be directed to the undersigned at the telephone number given below.

July 1, 2004
GREENBLUM & BERNSTEIN, P.L.C.
1950 Roland Clarke Place
Reston, VA 20191
(703) 716-1191

Respectfully submitted,
Hiroshi SHIKU et al.


Bruce H. Bernstein
Reg. No. 29,027

Fee 33,094
Bernstein

Group
1644

[illegible][illegible][illegible]

DATE CONSIDERED

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.